

## Executive

## In House Finance

**MEDCD1 Intravenous administration of ultrasound enhancing agents - sonographers****R.C. 4731.37**

No provision.

Authorizes a sonographer to administer intravenously ultrasound enhancing agents if the following conditions are met:

(1) No provision.

(1) A physician delegates that authority to the sonographer.

(2) No provision.

(2) The sonographer administers the agent in accordance with a written practice protocol developed by the facility where the physician practices.

(3) No provision.

(3) The delegating physician is physically present at the facility where the sonographer administers the agent.

(4) No provision.

(4) The sonographer has successfully completed an education and training program in sonography, is certified by a nationally recognized accrediting organization, and has successfully completed training in the intravenous administration of ultrasound enhancing agents.

No provision.

Specifies that the delegated authority to administer an ultrasound enhancing agent intravenously also includes the authority to insert, maintain, and remove an intravenous mechanism.

**Fiscal effect: Minimal.****MEDCD2 Legacy pain management study committee****Section: 335.20**

No provision.

Establishes the Legacy Pain Management Study Committee to study and evaluate the care and treatment of patients suffering from chronic or debilitating pain, in particular those who have been prescribed opioids for lengthy periods of time, often referred to as legacy patients.

No provision.

Includes the following as members of the committee: four members of the General Assembly, one representative of OhioMHAS, one representative of SMBO, one representative of PRX, one member representing patients, and one member representing prescribers.

Executive

In House Finance

No provision.	Requires the committee to consider several topics relating to legacy patients, including the availability of and access to pain management specialists in Ohio and the challenges associated with tapering opioid doses.
No provision.	Requires the committee, by December 1, 2024, to prepare and submit to the General Assembly a report of its recommendations for legislation to address the care and treatment of legacy patients.
	<b>Fiscal effect: Minimal.</b>

Executive	In House Finance
<b>MHACD21 Mobile-based opioid use disorder treatment</b>	
<b>Section: 337.95</b>	<b>Section: 337.95</b>
Requires OhioMHAS to operate a pilot program during FY 2024 and FY 2025 to provide opioid use disorder treatment to individuals in underserved regions selected by OhioMHAS, using medication units that are mobile.	Same as the Executive.
Specifies that the purpose of the program is to extend access to medication-assisted treatment to areas of the state lacking licensed opioid treatment programs and qualifying practitioners.	Same as the Executive.
Requires OhioMHAS to ensure that the services provided in mobile medication units used in the pilot program are those specified in relevant guidance issued by the U.S. Substance Abuse and Mental Health Services Administration.	Same as the Executive.
Requires PRX, SMBO, and NUR and any other state agency that OhioMHAS determines may be of assistance in accomplishing the pilot program's purpose to provide assistance upon request from OhioMHAS.	Same as the Executive.
Requires OhioMHAS to develop a plan for implementing and evaluating the pilot program within 60 days of the section's effective date.	Same as the Executive.
Requires OhioMHAS to complete a report of the findings obtained from the program within six months after the conclusion of the pilot program.	Same as the Executive.
Earmarks \$750,000 in each fiscal year in GRF ALI 336504, Community Innovations, to operate the pilot program.	Same as the Executive.